Summit to Present Advancements in Tissue Phenomics, Immuno-profiling,
Immuno-Oncology and Big Data
Definiens, the pioneer in Tissue Phenomics solutions for diagnostics and
clinical development, today announced that additional seating has been
added to the company’s upcoming annual conference, The International
Symposium for Tissue Phenomics, taking place April 25-26, 2017 in
Amsterdam, Netherlands. Tissue Phenomics, the use of unique tissue
signatures correlated to genetic and patient outcome data to develop
precise and powerful tissue-based diagnostics, continues to be a
decisive tool in oncology personalized medicine.
Definiens’ Symposium focuses on dynamic immunotherapy advancements and
the powerful convergence of computational science, bioinformatics and
digital pathology through the use of big data to support the promising
space of precision medicine.
This year’s event will feature presentations and discussions by leading,
distinguished researchers and speakers, including:
Corinne Berclaz, Imaging Specialist, Roche
Simone Bianco, IBM Research & Rock Star Employee
Ken Bloom, Head of Oncology & Immunotherapy, Human Longevity
Sebastian Brandner, Professor of Neuropathy, Head of Division,
University College London Institute of Neurology
Joachim Deeg, Professor of Medicine, Fred Hutch Cancer Research Center
Bernard Fox, Chief, Molecular & Tumor Immunology, Providence Cancer
Heike Grabsch, Professor of GI Pathology, University Medical Center of
James Gulley, Director of the Medical Oncology Service & Head,
National Cancer Center NIH
David Harrison, Symposium Co-Chair School of Medicine, University of
Babis Hatzikirou, Group Leader, Helmholtz Centre for Infection Research
Cyrus Hedvat, Director of Pathology, BMS
Ron Herbst, VP Oncology, MedImmune
Mischa Houtkamp, Senior Scientist, Genmab
Ryan Hutchinson, Immuno-oncology and Digital Pathology Fellow, Centre
for Translational Pathology, The University of Melbourne
Dirk Jäger, Professor of Medical Oncology, NCT Heidelberg
Bahija Jallal, EVP AstraZeneca and Head of MedImmune
Hartmut Juhl, Founder & CEO, Indivumed
Arne Ostman, Professor of Molecular Oncology, Pathology Karolinska
Lawrence Weiss, Medical Director, NeoGenomics
The annual Symposium addresses the most critical issues in oncology.
"The question is no longer whether digital pathology has a role in
clinical practice, but rather how revolutionary that role should be,"
says David Harrison, Symposium Co-Chair School of Medicine, North Haugh
University of St. Andrews.
Ralf Huss, CMO at Definiens shares that, “Tissue Phenomics is a core
competence for advanced image analysis solutions & multi-dimensional
applications. The use of Quantitative Pathology Biomarker Analysis is
becoming more prevalent and sophisticated in its use in Clinical Trials
and Diagnostics for Immuno-Oncology.”
From generic solutions to complex multidimensional applications Tissue
Phenomics has become the core technology for advanced image analysis and
data mining along the entire value chain. The use of quantitative and
informative pathology with added spatial information and computational
excellence provides an unprecedented opportunity for the identification
of novel biomarker solutions in clinical development and precision
diagnostics for immuno-oncology.
The symposium takes place from April 25-26, 2017 at the NH Grand Hotel
Krasnapolsky in Amsterdam. To register online please visit www.tissuephenomics.com
Definiens improves patient lives by unlocking the tissue phenome. In
oncology, therapeutic strategies have shifted from a direct assault on
cancer cells to recruiting the immune system for that purpose.
Definiens’ mission is to accelerate breakthroughs for this approach by
helping scientists leverage Tissue Phenomics to deepen understanding of
disease biology and immune system mechanisms, to bring multi-omics data
into a cancer-relevant context, and to facilitate the translation of new
insights into novel therapies and treatment strategies. Definiens vision
is to create unique patient profiles for an individualized standard of
care, where patients experience fewer side effects and live longer.
Definiens' Tissue Phenomics approach was awarded the 2013 Frost and
Sullivan Company of the Year Award for Global Tissue Diagnostics and
Pathology Imaging. For more information, please visit: www.definiens.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170411006337/en/
DefiniensLina WillisGlobal Marketing and Scientific